Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Sales (2020 - 2025)

Xeris Biopharma Holdings' Return on Sales history spans 6 years, with the latest figure at 0.13% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 21.0% year-over-year to 0.13%, compared with a TTM value of 0.0% through Dec 2025, up 27.0%, and an annual FY2025 reading of 0.0%, up 27.0% over the prior year.
  • Return on Sales for Q4 2025 was 0.13% at Xeris Biopharma Holdings, up from 0.01% in the prior quarter.
  • The five-year high for Return on Sales was 0.13% in Q4 2025, with the low at 3.09% in Q2 2021.
  • Average Return on Sales over 5 years is 0.83%, with a median of 0.43% recorded in 2022.
  • Year-over-year, Return on Sales tumbled -65bps in 2021 and then skyrocketed 205bps in 2022.
  • Tracing XERS's Return on Sales over 5 years: stood at 2.37% in 2021, then soared by 84bps to 0.39% in 2022, then increased by 23bps to 0.3% in 2023, then surged by 72bps to 0.09% in 2024, then soared by 252bps to 0.13% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Return on Sales are 0.13% (Q4 2025), 0.01% (Q3 2025), and 0.03% (Q2 2025).